Background: Cytokeratins (CK) are intermediate filaments that constitute the cytoskeletal structure of virtually all epithelial but also of some non-epithelial cells.They are divided into Type I (acidic cytokeratins, CK9 to 20) and Type II (basic cytokeratins, CK1 to 8) cytokeratins. Cytokeratin 8/18 antibody (identical with CAM 5.2) was known as specific for CK8 and CK18. This antibody detects most epithelial tissues and derived tumours. However, stratified epithelia and some non-stratified squamous cell carcinomas are negative for anti-Cytokeratin 8/18. Research indicates that squamous cell carcinomas derived from stratified epithelia show abnormal expression of Cytokeratin 8 and 18, although it is not known whether these proteins contribute to the malignant phenotype of the cells. Expression of Cytokeratin 8 and 18 in oral squamous cell carcinomas is an independent prognostic marker that indicates a poor prognosis.
Description: Rabbit polyclonal to Cytokeratin 8/18
Immunogen: KLH conjugated synthetic peptide derived from Cytokeratin 8/18
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 48-54 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
